Is apixaban (Eliquis) appropriate for patients on chronic dialysis?

Apixaban (Eliquis) in Dialysis Patients

Apixaban can be used in dialysis patients and appears safer than warfarin, though clinical trial data are limited and the FDA label acknowledges uncertainty about whether similar efficacy will be achieved.

Regulatory and Guideline Framework

The FDA label explicitly states that clinical efficacy and safety studies with Eliquis did not enroll patients with ESRD on dialysis 1. The dosing recommendations are based solely on pharmacokinetic and pharmacodynamic data showing that apixaban concentrations in dialysis patients are similar to those in the pivotal ARISTOTLE trial, but "it is not known whether these concentrations will lead to similar stroke reduction and bleeding risk" 1.

Guidelines show significant divergence on this issue 2:

• AHA/ACC/HRS (2019): Recommends apixaban 5.0 or 2.5 mg BID* for dialysis patients (*use 2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL)
• CHEST (2018): Recommends apixaban 5 mg BID (U.S. only) or warfarin with TTR >70%
• KDIGO (2018): Suggests "consider 2.5 mg BID" acknowledging equipoise with warfarin
• ESC (2016) and EHRA (2018): Do not recommend apixaban in dialysis patients

Evidence Supporting Use

Despite the lack of randomized trial data in dialysis patients, recent real-world evidence strongly favors apixaban over warfarin:

The most recent and highest quality evidence comes from a 2025 large cohort study that compared apixaban to warfarin in 1,364 matched pairs of patients with stage 5 CKD or ESRD on hemodialysis 3. This study demonstrated:

• Lower cerebrovascular events (SHR=0.69,95% CI 0.59-0.81)
• Lower bleeding-related outcomes (SHR=0.75,95% CI 0.64-0.87)
• Lower major bleeding (gastrointestinal bleeding SHR=0.77; blood transfusion SHR=0.73)
• Benefits consistent across gender, age, and dialysis status subgroups
• Warfarin's time in therapeutic range was only 44.4%

A 2026 real-world study in advanced CKD (stages 4-5,86% on hemodialysis) found apixaban associated with significantly fewer total bleeding events (44.4% vs 66.7%, p=0.04) and lower anticoagulant overdoses (5.6% vs 18.8%, p=0.04) compared to acenocoumarol, with no difference in thromboembolic events 4.

Dosing Considerations

For atrial fibrillation in dialysis patients, use the dose-reduction criteria from the FDA label 1:

• Standard dose: 5 mg twice daily
• Reduced dose: 2.5 mg twice daily if patient has ≥2 of the following:
  • Age ≥80 years
  • Body weight ≤60 kg
  • Serum creatinine ≥1.5 mg/dL

The optimal dose remains uncertain. The 2025 study noted that sensitivity analysis "lacks sufficient evidence to determine whether the 5 mg or 2.5 mg dose of apixaban is superior" 3. However, the FDA-recommended dosing algorithm based on age, weight, and creatinine provides a rational approach.

Pharmacokinetic Profile

Apixaban has favorable characteristics for dialysis patients 1:

• Only 27% renal excretion (73% non-renal elimination)
• Dialysis clearance is minimal (approximately 18 mL/min)
• Systemic exposure increases only 36% in ESRD patients post-dialysis compared to normal renal function
• Exposure is 14% lower on-dialysis versus off-dialysis

Critical Caveats

1. Warfarin concerns in dialysis patients 2:

   • Lower time in therapeutic range (TTR) than patients without CKD
   • Enhanced vascular calcification risk via Matrix Gla Protein inhibition
   • Risk of anticoagulant-related nephropathy
   • Requires 20% lower dosing but more labile INR

2. Bleeding risk increases with CKD progression: One study found bleeding events in 66% of stage 5 CKD patients versus 44% in stage 4 4, emphasizing the inherent hemorrhagic burden regardless of anticoagulant choice.

3. Traditional risk scores perform poorly: CHA2DS2-VASc and HAS-BLED show limited discriminatory capacity in advanced CKD populations 4.

4. Monitoring limitations: Standard coagulation tests don't reliably reflect apixaban activity. Emerging data suggest ROTEM may help predict bleeding risk 5.

Practical Recommendation

Use apixaban over warfarin in dialysis patients requiring anticoagulation for atrial fibrillation, applying FDA dose-reduction criteria. The real-world evidence consistently demonstrates superior safety without loss of efficacy 4, 3, 6, 7. While acknowledging the absence of randomized trial data in this population, the totality of evidence—including multiple large cohort studies, systematic reviews, and favorable pharmacokinetics—supports this approach over warfarin, which carries documented risks of poor INR control and vascular calcification in dialysis patients 2.